Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction

Journal of Medicinal Chemistry

Volumn 47, Issue 21, 2004, Pages 5085-5093

  Markowitz, Joseph ^a   Chen, Ijen ^b   Gitti, Rossi ^a   Baldisseri, Donna M ^a   Pan, Yongping ^b   Udan, Ryan ^a   Carrier, France ^a   MacKerell Jr , Alexander D ^b   Weber, David J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2[3 [(TERT BUTYLAMINO)CARBONYL]PHENYL] 1,3 DIOXOISONINDOLINE 5 CARBOXYLIC ACID; 4 [[4 [[(1,5 DIMETHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H PYRAZOL 4 YL)AMINO]SULFONYL]PHENYL]AMINO] 4 OXOBUTANOIC ACID; 5 [2 [[5 (3 CARBOXY 4 CHLOROPHENYL) 2 FURYL]METHYLENE]HYDRAZINO] 2 CHLOROBENZOIC ACID; 5 [[(2 MESITYL 1,3 DIOXO 2,3 DIHYDRO 1H ISOINDOL 5 YL)CARBONYL]AMINO]ISOPHTHALIC ACID; CALCIUM; N (2 BENZOYL 4 CHLOROPHENYL)IMIDODICARBONIMIDIC DIAMIDE HYDROCHLORIDE; N (2,3 DICHLOROPHENYL)IMIDODICARBONIMIDIC DIAMIDE; PENTAMIDINE ISETHIONATE; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN S100B; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; IC 50; MELANOMA; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT;

ANTINEOPLASTIC AGENTS; BINDING SITES; CALCIUM; CELL LINE, TUMOR; DATABASES, FACTUAL; HOLOENZYMES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MELANOMA; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NERVE GROWTH FACTORS; PENTAMIDINE; PROTEIN BINDING; S100 PROTEINS; SPECTROMETRY, FLUORESCENCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4744357517     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0497038     Document Type: Article

References (80)

1. Zimmer, D. B.; Cornwall, E. H.; Landar, A.; Song, W. The S100 protein family: history, function, and expression. Brain Res. Bull. 1995, 37, 417-429.
2. Zimmer, D. B.; Wright, P.; Weber, D. J. Molecular mechanism of S100-target protein interactions. J. Microsc. 2003, 324, 1003-1014.
3. Heizmann, C. W.; Fritz, G.; Schafer, B. W. S100 proteins: structure, functions and pathology. Front. Biosci. 2002, 7, 1356-1368.
4. Castets, F.; Griffin, W. S.; Marks, A.; Van Eldik, L. J. Transcriptional regulation of the human S100 beta gene. Mol. Brain Res. 1997, 46, 208-216.
5. Van Eldik, L. J.; Griffin, W. S. T. S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim. Biophys. Acta 1994, 7223, 398-403.
6. Mariggio, M. A.; Fulle, S.; Calissano, P.; Nicoletti, I.; Fano, G. The brain protein S-100ab induces apoptosis in PC12 cells. Neuroscience 1894, 60, 29-35.
7. McLendon, R. E.; Vick, W. W.; Bigner, S. H.; Bigner, D. D. Monoclonal antibodies and diagnosis of brain neoplasms. Cancer diagnosis in vitro using monoclonal antibodies; Marcel Dekker: New York, 1988; pp 31-66.
8. Camby, I.; Nagy, N.; Lopes, M. B.; Schafer, B. W.; Maurage, C. A.; et al. Supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins. Brain Pathol. 1999, 9, 1-19.
9. Takahashi, K.; Yoshino, T.; Akagi, T.; Miyatani, K.; Hayashi, K; et al. Natural killer (NK) activity of cultured S100 beta- positive T-leukemia cells. Virchows Arch. B 1990, 59, 159-164.
10. Takashi, M.; Sakata, T.; Nakano, Y.; Yamada, Y.; Miyake, K.; et al. Elevated concentrations of the beta-subunit of S100 protein in renal cell tumors in rats. Urol. Res. 1994, 22, 251-255.
11. Suzushima, H.; Asou, N.; Hattori, T.; Takatsuki, K. Adult T-cell leukemia derived from S100 beta positive double-negative (CD4- CD8-) T cells. Leuk. Lymphoma 1994, 13, 257-262.
12. Garbe, C.; Leiter, U.; Ellwanger, U.; Blaheta, H. J.; Meier, F.; et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow- up of high-risk melanoma patients. Cancer 2003, 97, 1737-1745.
13. Jury, C. S.; McAllister, E. J.; MacKie, R. M. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br. J. Dermatol. 2000, 143, 269-274.
14. Martenson, E. D.; Hansson, L. O.; Nilsson, B.; von Schoultz, E.; Mansson Brahme, E.; et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J. Clin. Oncol. 2001, 19, 824-831.
15. Banfalvi, T.; Gilde, K.; Gergye, M.; Boldizsar, M.; Kremmer, T.; et al. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Eur. J. Cancer 2003, 39, 164-169.
16. Guo, H. B.; Stoffel-Wagner, B.; Bierwirth, T.; Mezger, J.; Klingmuller, D. Clinical significance of serum S100 in metastatic malignant melanoma. [republished from Eur. J. Cancer 1995, 31A (6) (June), 924-928] Eur. J. Cancer 1995, 31A, 1898-1902.
17. Henze, G.; Dummer, R.; Joller-Jemelka, H. I.; Boni, R.; Burg, G. Serum S100-a marker for disease monitoring in metastatic melanoma. Dermatology 1997, 194, 208-212.
18. Buer, J.; Probst, M.; Franzke, A.; Duensing, S.; Haindl, J.; et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br. J. Cancer 1997, 75, 1373-1376.
19. Abraha, H. D.; Fuller, L. C.; Du Vivier, A. W.; Higgins, E. M.; Sherwood, R. A. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br. J. Dermatol. 1997, 137, 381-385.
20. Djukanovic, D.; Hofmann, U.; Sucker, A.; Rittgen, W.; Schadendorf, D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res. 2000, 20, 2203-2207.
21. Schmitz, C.; Brenner, W.; Henze, E.; Christophers, E.; Hauschild, A. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res. 2000, 20, 5059-5063.
22. Hansson, L. O.; von Schoultz, E.; Djureen, E.; Hansson, J.; Nilsson, B.; et al. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res. 1997, 17, 3071-3073.
23. Weber, D. J.; Rustandi, R. R.; Carrier, F.; Zimmer, D. B. Interaction of dimeric S100B(ββ) with the tumor suppressor protein: A model for Ca-dependent S100-target protein interactions; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2000; pp 469-487.
24. Rustandi, R. R.; Baldisseri, D. M.; Weber, D. J. Structure of the negative regulatory domain of p53 bound to S100B(ββ). Nat. Struct. Biol. 2000, 7, 570-574.
25. Lin, J.; Blake, M.; Tang, C.; Zimmer, D.; Rustandi, R. R.; et al. Inhibition of p53 transcriptional activity by the S100B calcium- binding protein. J. Biol. Chem. 2001, 276, 35037-35041.
26. Weber, D. J.; Markowitz, J.; Carrier, F.; MacKerell, A. D., Jr. Inhibitors of the S100-p53 Protein-Protein Interaction and Method of Inhibiting Cancer Employing the Same. In United States Patent and Trademark Office; University of Maryland, Baltimore: Baltimore, MD, 2003.
27. 2+-dependent interaction of S100B(ββ) with a peptide derived from p53. Biochemistry 1998, 37, 1951-1960.
28. Wilder, P. T.; Rustandi, R. R.; Drohat, A. C.; Weber, D. J. S100B-(ββ) inhibits the protein kinase C-dependent phosphorylation of a peptide derived from p53 in a Ca-dependent manner. Protein Sci. 1998, 7, 794-798.
29. Baudier, J.; Delphin, C.; Grundwald, D.; Khochbin, S.; Lawrence, J. J. Characterization of the tumor suppresor protein p53 as a protein kinase C substrate and a S100B-binding protein. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11627-11631.
30. Giaccia, A. J.; Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998, 12, 2973-2983.
31. Drohat, A. C.; Tjandra, N.; Baldisseri, D. M.; Weber, D. J. The use of dipolar couplings for determining the solution structure of rat apo-S100B. Protein Sci. 1999, 8, 800-809.
32. Drohat, A. C.; Baldisseri, D. M.; Rustandi, R. R.; Weber, D. J. Solution structure of calcium-bound rat S100B(ββ) as determined by NMR spectroscopy. Biochemistry 1998, 37, 2729-2740.
33. Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem., Int. Ed. 2002, 41, 2644-2676.
34. Stout, T. J.; Tondi, D.; Rinaldi, M.; Barlocco, D.; Pecorari, P.; Santi, D. V.; Kuntz, I. D.; Stroud, R. M.; Shoichet, B. K.; Costi, M. P. Structure-based design of inhibitors specific for bacterial thymidylate synthase. Biochemistry 1999, 38, 1607-1617.
35. Li, R.; Chen, X.; Gong, B.; Selzer, P. M.; Li, Z.; Davidson, E.; Kurzban, G.; Miller, R. E.; Nuzum, E. O.; McKerror, J. H.; Fletterick, R. J.; Gillmor, S. A.; Craik, C. S.; Kuntz, I. D.; Cohen, F. E.; Kenyon, G. L. Structure-based design of parasitic protease inhibitors. Bioorg. Med. Chem. 1986, 4, 1421-1427.
36. Schnecke, V.; Kuhn, L. A. Database Screening for HIV protease ligands: the influence of binding-site conformation and representation on ligand selectivity. Proc. Int. Intell. Syst. Mol. Biol. 1999, 242-251.
37. Selzer, P. M.; Chen, X.; Chan, V. J.; Cheng, M.; Kenyon, G. L.; Kuntz, I. D.; Sakanari, J. A.; Cohen, R. E.; McKerrow, J. H. Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp. Parasitol. 1997, 87, 212-221.
38. Tait, B. D.; Hagen, S.; Domagala, J.; Ellsworth, E. L.; Gajda, C.; Hamilton, H. W.; Prasad, J. V.; Ferguson, D.; Graham, N.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Humblet, C.; Lunney, E. A.; Pavlovsky, A.; Rubin, J.; Gracheck, S. J.; Baldwin, E. T.; Bhat, T. N.; Erikson, J. W.; Gulnik, S. V.; Liu, B. 4-Hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease. J. Med. Chem. 1997, 40, 3781-3792.
39. Mahajan, S.; Ghosh, S.; Sudbeck, E. A.; Zheng, Y.; Downs, S.; Hupke, M.; Uckun, F. M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy- beta-methyl-N-(2,5- dibromopheyl)propenamide. J. Biol. Chem. 1999, 274, 9587-9599.
40. Sudbeck, E.; Liu, X. P.; Narla, R. K.; Mahajan, S.; Ghosh, S.; Mao, C.; Uckun, F. N. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 1999, 5, 1569-1582.
41. Chen, I.-J.; Neamati, N.; Nicklaus, M. C.; Orr, A.; Anderson, L.; Barchi, J. J., Jr.; Kelly, J. A.; Pommier, Y.; MacKerell, A. D., Jr. Identification of HIV-1 integrase inhibitors via three- dimensional database searching using ASV and HIV-1 integrases as targets; Biorg. Med. Chem., in press.
42. Tracy, J. W.; Webster, L. T. Drugs used in the chemotherapy of protozoal infections. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; McGraw-Hill Companies: New York, 2001; pp 1109-1111.
43. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A Geometric Approach to Macromolecule-Ligand Interactions. J. Mol. Biol. 1982, 161, 269-288.
44. Ewing, T. J. A.; Kuntz, I. D. Critical Evaluation of Search Algorithms Used in Automated Molecular Docking. J. Comput. Chem. 1997, 18, 1175-1189.
45. Pan, Y.; Huang, N.; Cho, S.; MacKerell, A. D., Jr. Consideration of molecular weight during compound selection in virtual target- based database screening. J. Chem. Inf. Comput. Sci. 2003, 43, 267-272.
46. Chen, L-J., Neamati, N., MacKerell, A. D., Jr. Structure-Based Inhibitor Design Targeting HIV-1 Integrase. Curr. Drug Targets: Infect. Disord. 2002, 2, 217-234.
47. Inman, K. G.; Yang, R.; Rustandi, R. R.; Miller, K. E.; Baldisseri, D. M.; et al. Solution NMR structure of S100B bound to the high- affinity target peptide TRTK-12. J. Mol. Biol. 2002, 324, 1003-1014.
48. Leach, A. R.; Kuntz, I. D. Conformational analysis of flexible ligands in macromolecular receptor sites. J. Comput. Chem. 1992, 13, 730-748.
49. Ferrin, T. E.; Huang, C. C.; Jarvis, L. E.; Landridge, R. The MIDAS Display System. Mol. Graphics 1988, 6, 13-27.
50. Desjarlais, R. L.; Sheridan, R. P.; Dixon, J. S.; Kuntz, I. D.; Venkataraghaven, R. Docking Flexible Ligands to Macromolecular Receptors by Molecular Shape. J. Med. Chem. 1986, 29, 2149-2153.
51. Kuntz, I. D.; Meng, E. C.; Schoichet, B. K. Structure-Based Molecular Design. Acc. Chem. Res. 1994, 27, 117-123.
52. Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1984, 28, 849-857.
53. Meng, E. C.; Shoichet, B. K.; Kuntz, I. D. Automated Docking with Grid-Based Energy Evaluation. J. Comput. Chem. 1992, 13, 505-524.
54. Butina, D. Unsupervised data base clustering on daylight's fingerprint and Tanimoto similarity: a fast and automated way to cluster small and large data sets. J. Chem. Inf. Comput. Sci. 1999, 39, 747-750.
55. Bagby, S.; Tong, K. I.; Ikura, M. Optimization of protein solubility and stability for protein nuclear magnetic resonance. Methods Enzymol. 2001, 339, 20-41.
56. Jenkins, T. C.; Lane, A. N. AT selectivity and DNA minor groove binding: modelling, NMR and structural studies of the interactions of propamidine and pentamidine with d(CGCGAAT- TCGCG)2. Biochim. Biophys. Acta 1997, 1350, 189-204.
57. Morgan, D. M. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol. Biol. 1998, 79, 179-183.
58. Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 6, 277-293.
59. Johnson, M. A.; Rotondo, A.; Pinto, B. M. NMR studies of the antibody-bound conformation of a carbohydrate-mimetic peptide. Biochemistry 2002, 41, 2149-2157.
60. Mori, S.; Abeygunawardana, C.; Johnson, M. O.; van Zijl, P. C. Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation. J. Magn. Reson. B 1995, 108, 94-98.
61. Spera, S.; Bax, A. Empirical correlation between protein backbone conformation and Cα and Cβ/13-C nuclear magnetic resonance chemical shifts. J. Am. Chem. Soc. 1991, 113, 5490-5492.
62. 15N NMR study of gramicidin S in water and organic solvents. J. Am. Chem. Soc. 1984, 106, 1939-1941.
63. Edison, A. S.; Abildgaard, F.; Westler, W. M.; Mooberry, E. S.; Markley, J. L. Practical introduction to theory and implementation of multinuclear, multidimensional nuclear magnetic resonance experiments. Methods Enzymol. 1994, 239, 3-79.
64. Mayer, M.; Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 2001, 123, 6108-6117.
65. Yan, J.; Kline, A. D.; Mo, H.; Shapiro, M. J.; Zartler, E. R. The effect of relaxation on the epitope mapping by saturation transfer difference NMR. J. Magn. Reson. 2003, 163, 270-276.
66. Piotto, M.; Saudek, V.; Sklenar, V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J. Biomol. NMR 1992, 2, 661-665.
67. Scott, K.; Stonehouse, J.; Keeler, J.; Hwang, T. L.; Shaka, A. J. J. Am. Chem. Soc. 1995, 117, 4199-4200.
68. Bax, A.; Davis, A. L. J. Magn. Reson. 1985, 65, 355-360.
69. Jeener, J.; Meier, B. H.; Bachmann, P.; Ernst, R. R. Investigation of exchange processes by two-dimensional NMR. J. Chem. Phys. 1979, 71, 4546-4553.
70. Bax, A.; Marion, D. J. Biomol. NMR. 1988, 78, 186-191.
71. Bax, A.; Summers, M. F. J. Am. Chem. Soc. 1986, 108, 2093-2094.
72. Weber, D. J.; Gittis, A. G.; Mullen, G. P.; Abeygunawardana, C.; Lattman, E. E.; et al. NMR docking of a substrate into the X-ray structure of staphylococcal nuclease. Proteins 1992, 13, 275-287.
73. Weber, D. J.; Libson, A. M.; Gittis, A. G.; Lebowitz, M. S.; Mildvan, A. S. NMR docking of a substrate into the X-ray structure of the Asp-21 - Glu mutant of staphylococcal nuclease. Biochemistry 1994, 33, 8017-8028.
74. Kleywegt, F. J.; Jones, T. A. Model-building refinement practice. Methods Enzymol. 1997, 277, 208-230.
75. Schwieters, C. D.; Kuszewski, J. J.; Tjandra, N.; Marius Clore, G. The Xplor-NIH NMR molecular structure determination package. J. Magn. Reson. 2003, 160, 65-73.
76. Schwieters, C. D.; Clore, G. M. The VMD-XPLOR visualization package for NMR structure refinement. J. Magn. Reson. 2001, 149, 239-244.
77. Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950.
78. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high- affinity ligands for proteins. Science 1997, 278, 497-499.
79. Fesik, S. W. NMR structure-based drug design. J. Biomol. NMR 1994, 3, 261-269.
80. Wüthrich, K. NMR of proteins and nucleic acids; John Wiley: New York, 1986.